EMA Authorised: Pluvicto (lutetium (177Lu) vipivotide tetraxetan) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Pluvicto (lutetium-177 vipivotide tetraxetan) for metastatic castration-resistant prostate cancer. It is a PSMA-targeted radioligand therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms, Castration-Resistant. MAH: Novartis Europharm Limited. Decision date: 17/02/2026